Sold
Available
IBL-26-2849

Composition containing a sesquiterpene derivative as an active ingredient for muscle strengthening, muscle enhancement, muscle differentiation, muscle regeneration, or inhibiting sarcopenia

Listed on
2026-10-27
Composition for Improving Sarcopenia by Promoting Muscle Protein Synthesis Based on Alpha-Cedrene

This technology is a composition for preventing and treating muscle diseases that uses the sesquiterpene derivative alpha-cedrene or its pharmaceutically acceptable salts as an active ingredient. It is widely applicable in pharmaceuticals, health functional foods, and cosmetic compositions for muscle regeneration, increasing muscle mass, and improving muscle function.

As aging leads to an increase in sarcopenia, the risks of gait impairment, insulin resistance, and cardiovascular disease are rising, yet there have been no approved drugs for treating sarcopenia. While myostatin inhibitors and drug repurposing approaches are under development, there has been a lack of practical, commercialized alternatives.

This technology enables alpha-cedrene to increase the expression of p-4E-BP1 and p-p70S6K in the muscle protein synthesis pathway while reducing the expression of MuRF1, MaFbx, and Myostatin—which are involved in muscle protein degradation—at the mRNA level. This simultaneously induces muscle differentiation, regeneration, and strength enhancement. It can be applied to sarcopenia treatments and health supplements for senior muscle strength, providing a new material for the market of geriatric muscle diseases that currently lacks effective treatments.

‍

‍

Key Features:
  • A pharmaceutical composition for preventing or treating muscle diseases containing a sesquiterpene derivative, alpha-cedrene, or its pharmaceutically acceptable salts as an active ingredient
  • A composition that increases the expression of p-4E-BP1 and p-p70S6K proteins and decreases the expression of MuRF1, MaFbx, or Myostatin
  • A pharmaceutical composition targeting one or more muscle diseases, including muscular atrophy, muscular dystrophy, cachexia, ALS, and sarcopenia
  • A health functional food composition containing alpha-cedrene as an active ingredient for muscle regeneration, increasing muscle mass, or improving muscle function

‍

Yonsei University
Park Tae-sun
Document
Date of application:
2017-06-23
|
Patent registration number:
10-2061933
Industry
healthcare•pharm
food•beverage
Technology
Bio/Pharmaceutical
Country
Korea
EPO
Family Patent

EP3643302B1, US2021-0369640A1, WO2018-236186A1

Price
Price negotiable
Subscribe to our newsletter to receive the latest patent information faster than anyone else.
← Back to list